Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BMS' ZEPOSIA Wins Approval for RMS | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

BMS’ ZEPOSIA Wins Approval for RMS

Oral medication offers RMS patients an initiation with no genetic test and no label-based first-dose observation required.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Bristol-Myers Squibb Co. received approval from the U.S. FDA for ZEPOSIA (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
 
ZEPOSIA, an oral medication taken once daily, is the only approved sphingosine-1-phosphate (S1P) receptor modulator that offers RMS patients an initiation with no genetic test and no label-based first-dose observation required for patients.

Multiple sclerosis (MS) is a disease in which the immune system attacks the protective myelin sheath that covers the nerves, creating damaging lesions that make it harder for signals to travel between each nerve cell. This “signal breakdown” can lead to symptoms and relapses.
 
The approval is based on data from head-to-head RMS studies with an active comparator assessing the safety and efficacy of ZEPOSIA as compared to Biogen’s AVONEX (interferon beta-1a).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters